What is the current market size and future outlook for the minimally invasive glaucoma surgery (migs) devices market?
The minimally invasive glaucoma surgery (MIGS) devices market size has grown exponentially in recent years. It will grow from $0.7 billion in 2024 to $0.9 billion in 2025 at a compound annual growth rate (CAGR) of 28.3%. The growth in the historic period can be attributed to increased awareness for the prevention of blindness, increased investments in healthcare infrastructure, increased patient awareness surrounding advanced corrective vision treatments, rise in awareness surrounding advanced corrective vision treatments, increased government initiatives.
The minimally invasive glaucoma surgery (MIGS) devices market size is expected to see exponential growth in the next few years. It will grow to $2.42 billion in 2029 at a compound annual growth rate (CAGR) of 28.1%. The growth in the forecast period can be attributed to increasing prevalence of eye disorders like glaucoma, rise in geriatric population, growing healthcare infrastructure, growing need for safer and more efficient treatment. Major trends in the forecast period include adoption of MIGS devices, advancements in technology, development of innovative minimally invasive glaucoma surgery devices, development of advanced implantable devices, advances in ophthalmic technology.
Get Your Free Sample of The Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15863&type=smp
What are the key drivers behind the rapid expansion of the minimally invasive glaucoma surgery (migs) devices market?
The increasing prevalence of eye disorders is expected to propel the growth of minimally invasive glaucoma surgery (MIGS) devices going forward. Eye disorders encompass a wide range of conditions that affect the eyes and vision. The prevalence of eye disorders is increasing due to lifestyle changes, environmental influences, and aging populations. Minimally invasive glaucoma surgery (MIGS) devices are innovative tools utilized in managing various eye diseases, primarily focusing on reducing intraocular pressure (IOP) to prevent or control glaucoma progression. For instance, in 2024, according to the National Eye Institute, a US-based government agency, around 2.2 million Americans will be blind or partially blind by 2030. Therefore, the increasing prevalence of eye disorders drives the minimally invasive glaucoma surgery (MIGS) devices market.
What is the segmentation for the minimally invasive glaucoma surgery (migs) devices market?
The minimally invasive glaucoma surgery (MIGS) devices market covered in this report is segmented –
1) By Product: Valves, Glaucoma Drainage Implant, Glaucoma Tube Shunts, Stents, Other Products
2) By Surgery: Glaucoma In Conjunction With Cataract, Stand Alone Glaucoma
3) By Target: Trabecular Meshwork, Suprachoroidal Space, Other Targets
4) By Distribution Channel: Direct Tender, Retail Sales
5) By End User: Ophthalmology Clinics, Ambulatory Surgery Centers (ASCS), Other End Users
Subsegments:
1) By Valves: Micro Shunt Valves, Non-penetrating Valves
2) By Glaucoma Drainage Implant: Scleral Drainage Implants, Subconjunctival Drainage Implants
3) By Glaucoma Tube Shunts: Ahmed Tube Shunt, Baerveldt Tube Shunt
4) By Stents: Ab-Interno Stents, Ab-Externo Stents
5) By Other Products: Cyclodestructive Devices, Trabecular Bypass Devices
Order your report now for swift delivery
Who are the most influential companies in the minimally invasive glaucoma surgery (migs) devices market?
Major companies operating in the minimally invasive glaucoma surgery (MIGS) devices market are AbbVie Inc., Novartis AG, Alcon Inc., Bausch Health Companies Inc., Bausch & Lomb Incorporated Inc., Carl Zeiss Meditec AG, Santen Pharmaceutical Co. Ltd., Johnson & Johnson Vision Care Inc., Lumenis Ltd., Staar Surgical Company, Glaukos Corporation, Sight Sciences Inc., Ocular Therapeutix Inc., Iridex Corporation, Ellex Medical Lasers Ltd., New World Medical Inc., MicroSurgical Technology Inc., Nova Eye Medical Limited, Asico LLC, Ziemer Ophthalmic Systems AG, Transcend Medical, iSTAR Medical SA, Ivantis Group Inc., Allergan, InnFocus Inc.
What are the most influential trends expected to drive the minimally invasive glaucoma surgery (migs) devices market forward?
Major companies operating in the minimally invasive glaucoma surgery (MIGS) devices market are focused on developing innovative products, such as stent injectable systems, to address unmet needs in glaucoma management and improve patient outcomes. A stent injectable system is a minimally invasive glaucoma surgery (MIGS) device that delivers and implants a small stent into the body through an injection-like procedure, often using a specialized delivery mechanism that is commonly used in minimally invasive surgeries to treat conditions such as blocked or narrowed blood vessels. For instance, in August 2022, Glaukos Corporation, a US-based ophthalmic medical technology company, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the iStent Infinite Trabecular Micro-Bypass System. The iStent Infinite is a novel three-stent injectable system designed to provide foundational, 24/7 intraocular pressure (IOP) control for patients with primary open-angle glaucoma (POAG) whose IOP is uncontrolled by prior medication and surgical therapy.
What are the major regional insights for the minimally invasive glaucoma surgery (migs) devices market, and which region holds the top position?
North America was the largest region in the minimally invasive glaucoma surgery (MIGS) devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimally invasive glaucoma surgery (MIGS) devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does The Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report 2025 Offer?
The minimally invasive glaucoma surgery (migs) devices market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Minimally invasive glaucoma surgery (MIGS) devices are medical instruments designed to lower intraocular pressure (IOP) in patients with glaucoma through less invasive surgical techniques compared to traditional glaucoma surgeries. These devices aim to reduce the risk of complications, shorten recovery time, and improve patient outcomes by offering a safer and less invasive option for patients needing surgical intervention to manage their condition.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15863
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
